INDIA SEMEN ANALYSIS MARKET FORECAST 2025-2032

Primary infertility affects an estimated 3.9% to 16.8% of couples in India, with male factors contributing to 40–50% of all cases. This high prevalence of male infertility is attributed to a combination of factors, including lifestyle choices, obesity, and smoking. 

The prevalence of obesity in India stands at 40.3%, varying across regions, and is known to negatively impact fertility. Additionally, approximately 10.38% of men in India are current smokers, and 21.38% use smokeless tobacco, both of which have been linked to reduced semen quality assessment and sperm health checks.

India’s demographic structure presents a significant opportunity for market growth, with the reproductive age group (15–49 years) comprising a substantial portion of the population.

The India Semen Analysis Market: 6.86% CAGR (2025-2032)

Need a custom report or have specific data requirements? Let us know!

Data indicates that 72.8% of women within this age range have access to family planning services, highlighting the potential market for fertility-related diagnostics and treatments, such as male fertility test options. The use of semen analysis tests continues to rise, reflecting the growing need for precise diagnostics in fertility solutions.

Technological advancements, including AI-driven innovations, are reshaping the semen analysis testing market in India. These tools enable accurate assessments of key sperm parameters, such as count, motility, and morphology, while addressing the need for convenient and private diagnostic solutions. 

The growing adoption of at-home semen test kits aligns with the rising demand for accessible reproductive health technologies. Semen motility check and semen quality assessment are becoming more precise with the integration of AI and automated semen analyzers, ensuring higher accuracy and reliability.

Microscopic examination remains a widely used method for laboratory testing of semen in clinical settings due to its affordability and ability to meet basic diagnostic needs. However, advanced technologies, including CASA systems and AI-powered tools, are increasingly being adopted for their superior accuracy and efficiency. 

These innovations address diagnostic challenges while offering reliable solutions for both clinical and home-based testing, boosting future demand in the semen analysis market. The integration of manual semen analyzers and AI technologies is expected to further improve semen analysis testing, offering solutions for both male fertility and male infertility.

The India semen analysis market is segmented into diagnostic technique, testing kits and reagents, age group, and end-user. The end-user category is further classified into hospitals, fertility centers, diagnostic laboratories, and other end-users.

Diagnostic laboratories play a pivotal role within the end-user segment, offering specialized and accessible semen analysis services to patients across urban and rural areas. These laboratories are equipped with advanced diagnostic tools, including CASA systems and traditional microscopy, to deliver accurate assessments of sperm parameters such as count, motility, and morphology. 

In India, diagnostic laboratories often serve as the first point of contact for individuals seeking fertility evaluations, providing critical data that aids in the diagnosis and treatment of male infertility.

With a high prevalence of male infertility and a substantial population in the reproductive age group, the demand for semen analysis and fertility diagnostics is expected to grow significantly. 

Addressing challenges such as poor awareness and access to healthcare, alongside the integration of innovative technologies, will be critical in unlocking the full potential of the Indian semen analysis market.

Some of the leading players in the India semen analysis market include bioMérieux SA, Cooper Companies Inc, DNA Diagnostics Center, Sperm Processor Pvt Ltd, Leja Products BV, etc.

Sperm Processor Pvt. Ltd., established in 1998 and based in Aurangabad, India, specializes in the research, development, manufacturing, and marketing of a comprehensive range of andrology laboratory products. Their offerings include Sperm Function Test (SFT) kits, instruments, accessories, plasticware, disposables, and processing media, all designed to enhance the performance of andrology labs. 

The company is ISO 13485:2003 certified, ensuring adherence to international quality standards. Their flagship product, SpermSoft, is a Computer Assisted Semen Analyzer (CASA) with an expert mode, providing advanced semen analysis capabilities.